Mitobrin (Tobramycin)

Tobramycin binds to the bacterial 30S ribosomal subunit, causing misreading of messenger RNA and halting protein synthesis. This bactericidal action eliminates susceptible ocular pathogens.

The dosing regimen for Mitobrin is determined by the prescribing ophthalmologist based on the severity of the infection, patient age, and clinical response. The prescriber will specify the exact volume and frequency.

Safety data for tobramycin in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the Mitobrin product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mitobrin (tobramycin) belongs to the aminoglycoside class, offering strong activity against Gram‑negative ocular pathogens. Compared with fluoroquinolone eye drops, tobramycin may have a narrower spectrum but is effective for many common bacterial conjunctivitis cases and is often chosen when resistance to fluoroquinolones is a concern.

Mitobrin should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain potency.

Mitobrin is administered by a qualified eye‑care professional via a subconjunctival injection. The exact technique, volume and frequency are determined by the ophthalmologist according to the infection’s severity and location.

Serious risks include severe allergic reactions such as anaphylaxis, significant ocular inflammation or corneal ulceration, and rare systemic toxicities like ototoxicity or nephrotoxicity, especially if systemic absorption occurs or if combined with other nephrotoxic agents.

Patients with a known hypersensitivity to tobramycin, other aminoglycosides, or any component of the formulation should not receive Mitobrin. Additionally, individuals with severe renal impairment should avoid use unless specifically directed by a physician.